Antiprion compounds that reduce PrPSc levels in dividing and stationary-phase cells

During prion diseases, a normally benign, host protein, denoted PrP^C, undergoes alternative folding into the aberrant isoform, PrP^Sc. We used ELISA to identify and confirm hits in order to develop leads that reduce PrP^Sc in prion-infected dividing and stationary-phase mouse neuroblastoma (ScN2a-cl3) cells. We tested 52,830 diverse small molecules in dividing cells and 49,430 in stationary-phase cells. This led to 3100 HTS and 970 single point confirmed (SPC) hits in dividing cells, 331 HTS and 55 confirmed SPC hits in stationary-phase cells as well as 36 confirmed SPC hits active in both. Fourteen chemical leads were identified from confirmed SPC hits in dividing cells and three in stationary-phase cells. From more than 682 compounds tested in concentration–effect relationships in dividing cells to determine potency (EC₅₀), 102 had EC₅₀ values between 1 and 10 μM and 50 had EC₅₀ values of <1 μM; none affected cell viability. We observed an excellent correlation between EC₅₀ values determined by ELISA and Western immunoblotting for 28 representative compounds in dividing cells (R² = 0.75; p <0.0001). Of the 55 confirmed SPC hits in stationary-phase cells, 23 were piperazine, indole, or urea leads. The EC₅₀ values of one indole in stationary-phase and dividing ScN2a-cl3 cells were 7.5 and 1.6 μM, respectively. Unexpectedly, the number of hits in stationary-phase cells was ～10% of that in dividing cells. The explanation for this difference remains to be determined.